Description
What Imbruvica is?
IMBRUVICA is a kinase inhibitor indicated for the treatment of adult patients with:
• Mantle cell lymphoma (MCL) who have received at least one prior therapy.
• Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL).
• Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion.
• Waldenström’s macroglobulinemia (WM).
• Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
• Chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy
What Ibrutinib is?
Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that binds permanently to a protein, Bruton’s tyrosine kinase (BTK), that is important in B cells. It is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström’s macroglobulinemia.
Ibrutinib is used to treat chronic lymphocytic leukemia (CLL), Waldenström’s macroglobulinemia, and as a second-line treatment for mantle cell lymphoma, marginal zone lymphoma, and chronic graft vs host disease.
